氙製藥公司
US ˙ NasdaqGM ˙ CA98420N1050

SecurityXENE / Xenon Pharmaceuticals Inc.
InstitutionState Street Corp
Latest Disclosed Ownership1,720,533 shares
Latest Disclosed Value $ 100,048,994
State Street Corp reports 15.27% increase in ownership of XENE / Xenon Pharmaceuticals Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 1,720,533 shares of Xenon Pharmaceuticals Inc. (US:XENE) valued at $100,048,994 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,492,550 shares of Xenon Pharmaceuticals Inc.. This represents a change in shares of 15.27% during the quarter. The current value of the position is $91,171,044 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 1,720,533 227,983 15.27 100,049 49.56 0.0035
2026-02-13 2025-12-31 13F XENON PHARMACEUTICALS COM 98420N105 1,492,550 26,083 1.78 66,896 13.62 0.0022
2025-11-14 2025-09-30 13F XENON PHARMACEUTICALS COM 98420N105 1,466,467 86,007 6.23 58,879 36.27 0.0020
2025-08-14 2025-06-30 13F XENON PHARMACEUTICALS COM 98420N105 1,380,460 1,074,840 351.69 43,208 321.42 0.0016
2025-05-15 2025-03-31 13F XENON PHARMACEUTICALS COM 98420N105 305,620 16,898 5.85 10,254 -9.40 0.0004
2025-02-14 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 288,722 9,209 3.29 11,318 2.84 0.0004
2024-11-14 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 279,513 32,701 13.25 11,004 14.35 0.0004
2024-08-14 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 246,812 4,172 1.72 9,623 -7.87 0.0004
2024-05-15 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 242,640 15,600 6.87 10,446 -0.11 0.0005
2024-02-14 2023-12-31 13F XENON PHARMACEUTICALS COM 98420N105 227,040 14,670 6.91 10,457 44.15 0.0005
2023-11-14 2023-09-30 13F XENON PHARMACEUTICALS COM 98420N105 212,370 -180 -0.08 7,255 -11.35 0.0004
2023-08-14 2023-06-30 13F XENON PHARMACEUTICALS COM 98420N105 212,550 5,094 2.46 8,183 10.22 0.0004
2023-05-15 2023-03-31 13F XENON PHARMACEUTICALS COM 98420N105 207,456 10,020 5.08 7,425 -4.62 0.0004
2023-05-15 2022-12-31 13F/A-99 XENON PHARMACEUTICALS COM 98420N105 197,436 27,065 15.89 7,785 26.57 0.0005
2023-05-15 2022-12-31 13F XENON PHARMACEUTICALS COM 98420N105 197,436 27,065 7,785 0.0005
2022-11-15 2022-09-30 13F XENON PHARMACEUTICALS COM 98420N105 170,371 -26,850 -13.61 6,150 2.52 0.0004
2022-08-15 2022-06-30 13F XENON PHARMACEUTICALS COM 98420N105 197,221 25,234 14.67 5,999 14.09 0.0004
2022-05-16 2022-03-31 13F XENON PHARMACEUTICALS COM 98420N105 171,987 10,738 6.66 5,258 4.39 0.0003
2022-02-14 2021-12-31 13F XENON PHARMACEUTICALS COM 98420N105 161,249 13,802 9.36 5,037 123.57 0.0002
2021-11-15 2021-09-30 13F XENON PHARMACEUTICALS COM 98420N105 147,447 16,852 12.90 2,253 -7.36 0.0001
2021-08-16 2021-06-30 13F XENON PHARMACEUTICALS COM 98420N105 130,595 32,507 33.14 2,432 38.50 0.0001
2021-07-09 2021-03-31 13F/A-1 XENON PHARMACEUTICALS COM 98420N105 98,088 4,702 5.04 1,756 22.28 0.0001
2021-05-17 2021-03-31 13F XENON PHARMACEUTICALS COM 98420N105 98,088 4,702 1,756 0.0001
2021-02-16 2020-12-31 13F XENON PHARMACEUTICALS COM 98420N105 93,386 3,839 4.29 1,436 44.90 0.0001
2020-11-10 2020-09-30 13F XENON PHARMACEUTICALS COM 98420N105 89,547 2,883 3.33 991 -8.83 0.0001
2020-08-14 2020-06-30 13F XENON PHARMACEUTICALS COM 98420N105 86,664 67,686 356.66 1,087 405.58 0.0001
2020-06-19 2020-03-31 13F/A-1 XENON PHARMACEUTICALS COM 98420N105 18,978 -1,382 -6.79 215 -19.48 0.0000
2020-05-11 2020-03-31 13F XENON PHARMACEUTICALS COM 98420N105 18,978 -1,382 215 18.8813
2020-02-06 2019-12-31 13F XENON PHARMACEUTICALS COM 98420N105 20,360 -304 -1.47 267 43.55 0.0000
2019-11-14 2019-09-30 13F XENON PHARMACEUTICALS COM 98420N105 20,664 0 0.00 186 -8.82 0.0000
2019-08-14 2019-06-30 13F XENON PHARMACEUTICALS COM 98420N105 20,664 0 0.00 204 -2.86 0.0000
2019-05-15 2019-03-31 13F XENON PHARMACEUTICALS COM 98420N105 20,664 -624 -2.93 210 56.72 0.0000
2019-02-12 2018-12-31 13F XENON PHARMACEUTICALS COM 98420N105 21,288 1,788 9.17 134 -47.86 0.0000
2018-11-09 2018-09-30 13F XENON PHARMACEUTICALS Common equity shares 98420N105 19,500 19,500 257 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.